ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Follicular Lymphoma Management: What Is the New Order?

SOHO 2023 Eleventh Annual Meeting

B. Kahl

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

Christopher Flowers

FL Updates: Is There a Standard 1L Treatment?

SOHO Brazil 2024

B. Kahl

Summary of Recent Advances in Follicular Lymphoma

Louisville Hematology Highlights

S. Gaballa

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Tazemetostat in R/R FL: Impact of EZH2 Mutational Status on PFS

Bruce D. Cheson

Standards of Care and Future Directions in FL

Martin Dreyling

Treatment Landscape in Follicular Lymphoma

Mitchell Smith

Tazemetostat in Older Frail Adults With Follicular Lymphoma

Erin Mulvey

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith